Science Spotlight: Multi-epitope antivirals, metastatic transition, and more

Researchers from Icahn School of Medicine at Mount Sinai, including Antenna Biotech Inc. co-founder Yi Shi, developed a platform that can display over 20 antibodies, designed to bind multiple conserved and neutralizing epitopes on a pathogen.

The platform, dubbed adaptive multi-epitope targeting with enhanced avidity (AMETA), conjugates bispecific single-domain antibody fragments to a human IgM scaffold. The authors used structure-guided design to make a construct targeting multiple epitopes of SARS-CoV-2 that surpassed monomeric antibody potency over a million-fold...